As stated in the previous letter, the vaccinesrecommended for the 2018/19 season continue to be recommended for the 2019/20 season. Both are currently licensed and available to order for use in the United Kingdom:
- The standard egg cultured quadrivalent inactivated vaccine (QIVe) will continue to be recommended for 18 to 64-year olds in clinical at-risk groups and other eligible groups, including frontline health and social care workers; and
- The adjuvanted trivalent inactivated vaccine (aTIV) will continue to be recommended for individuals aged 65 years and over.
NHS England has determined that the high-dose trivalent vaccine (TIV-HD), which has also been granted licensed status, has a significantly higher list price and will therefore not be commissioned by NHS England or reimbursed for use in the Flu Vaccination Service 2019/20. Contractors are therefore advised not to purchase or administer this product for the Advanced Flu Vaccination Service.
A summary table detailing indicative age groups, licensure status and NHS cost per dose is included as an annex in the letter.
Click here to view the letter